Inventor profile of:

Abraham Pinter

City:

Brooklyn, New York

Country:

United States

Published Applications:

11

Last publication date:

2025-11-13

Top Assignees for applications by Abraham Pinter

The entities that hold a legal rights for patent applications filed by inventor Pinter Abraham:

Recent patent applications by Pinter Abraham

Abraham Pinter from Brooklyn, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-11-13
US20250347699A1
Physics

SARS-COV-2 POLYPEPTIDE, ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF

#2 | 2022-06-02
US20220168420A1
Human necessities

Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of infections

#3 | 2021-09-30
US20210302424A1
Physics

METHODS FOR DUAL DETECTION AND DIFFERENTIATION OF INFECTION BY MYCOBACTERIUM TUBERCULOSIS COMPLEX AND NONTUBERCULOUS MYCOBACTERIA

#4 | 2020-10-08
US20200316199A1
Human necessities

Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of infections

#5 | 2019-02-07
US20190038747A1
Human necessities

Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of infections

#6 | 2016-09-08
US20160257720A1
Chemistry; metallurgy

HIV-1 antigens with discrete conformational forms in the V1/V2 domain and methods of use thereof

#7 | 2015-06-25
US20150175679A1
Chemistry; metallurgy

Neutralizing antibodies that bind to the HIV-1 Env V2 critical neutralization domain

#8 | 2011-12-22
US20110311569A1
Chemistry; metallurgy

HIV-1 Peptides, Nucleic Acids, and Compositions and Uses Thereof

#9 | 2011-04-21
US20110091491A1
Human necessities

HIV-1 GP41 neutralization domain and use thereof

#10 | 2009-04-16
US20090098144A1
Chemistry; metallurgy

Immunogen comprising the HIV GP120 V3 loop in a conformation that induces broadly neutralizing antibodies

#11 | 2005-03-17
US20050058983A1
Chemistry; metallurgy

Use of transgenic mice for the efficient isolation of novel human monoclonal antibodies with neutralizing activity against primary HIV-1 strains and novel HIV-1 neutralizing antibodies

InventorID:

1204330 ⎘